Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in T2DM and Obesity (MitoSema)
NCT04854083Phase 4Unknown
- Start
- Feb 2022
- Primary completion
- Aug 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing Semaglutide with Placebo (2 arms). Primary endpoint: Hemoglobin A1c at 12 months. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04854083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854083.